Blocking the PD-1/PD-L1 signaling by using immunotherapy drugs can prevent tumor immune escape, increasing the anti-tumor activity of immune cells by improving T-cell activation and cytotoxic T cell killing activity [108,123,126]. Here, PDCD1 is linked to neoplasm.